LH

+ Watchlist + Portfolio

Labcorp Holdings Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $304.60
52-Week Range: $244.52 – $341.80
Market Cap: $25.02B
P/E (TTM): 25.52
EPS (TTM): 12.09
Dividend Yield: 0.93%

Advanced Metrics

Price/Book: 2.90
PEG Ratio: 1.20
Return on Equity: 11.73%
Return on Assets: 5.53%
Gross Margin: 28.88%
Operating Margin: 12.24%
Profit Margin: 6.99%
Current Ratio: 1.80
Debt/Equity: 0.79
Total Debt: $6.82B
Free Cash Flow: $892.05M
Revenue Growth: 5.80%
Earnings Growth: 28.20%
Enterprise Value: $31.72B

LH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$11.86B	$12.16B	$13.01B	$13.95B
Cost of Revenue	$8.15B	$8.80B	$9.38B	$9.94B
Gross Profit	$3.71B	$3.36B	$3.62B	$4.01B
Selling, General & Admin	$1.76B	$2.02B	$2.23B	$2.22B
Operating Expenses	$1.96B	$2.24B	$2.49B	$2.50B
Operating Income	$1.75B	$1.12B	$1.14B	$1.52B
EBITDA	$1.95B	$1.35B	$1.81B	$2.01B
Pretax Income	$1.24B	$568.90M	$959.50M	$1.11B
Income Tax	$233.90M	$188.50M	$212.40M	$229.80M
Net Income	$1.28B	$418.00M	$746.00M	$876.50M
Diluted EPS	13.97	4.77	8.84	10.46
Diluted Shares	91.60M	87.60M	84.40M	83.80M

LH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$320.60M	$536.80M	$1.52B	$532.30M
Receivables	$2.00B	$2.10B	$2.10B	$2.26B
Inventory	$470.60M	$474.60M	$493.20M	$534.70M
Current Assets	$4.63B	$3.77B	$4.81B	$4.02B
Total Assets	$20.16B	$16.73B	$18.38B	$18.39B
Current Liabilities	$3.08B	$3.23B	$3.33B	$2.82B
Long-Term Debt	$5.04B	$4.05B	$5.33B	$5.08B
Total Debt	$6.25B	$5.95B	$7.27B	$6.53B
Total Liabilities	$10.04B	$8.83B	$10.31B	$9.76B
Retained Earnings	$10.58B	$7.89B	$8.30B	$8.64B
Shareholders' Equity	$10.10B	$7.88B	$8.05B	$8.62B
Working Capital	$1.55B	$540.20M	$1.48B	$1.20B
Net Debt	$5.02B	$4.52B	$4.81B	$5.05B

LH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.96B	$1.33B	$1.59B	$1.64B
Capital Expenditure	-$429.30M	-$453.60M	-$489.90M	-$434.50M
Free Cash Flow	$1.53B	$874.10M	$1.10B	$1.21B
Depreciation & Amortisation	$537.20M	$577.30M	$643.50M	$681.10M
Stock-Based Compensation	$116.80M	$128.70M	$116.70M	$125.80M
Investing Cash Flow	-$1.65B	-$1.17B	-$1.37B	-$1.19B
Financing Cash Flow	-$1.32B	-$59.30M	$779.90M	-$1.46B
Dividends Paid	-$195.20M	-$254.00M	-$243.10M	-$240.70M
Share Repurchases	-$1.10B	-$1.00B	-$250.10M	-$450.00M
Net Change in Cash	-$1.13B	$96.90M	$998.90M	-$1.01B

LH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.35B	$3.53B	$3.56B	$3.52B	$3.54B	$3.73B
Cost of Revenue	$2.40B	$2.48B	$2.54B	$2.52B	$2.52B	$2.62B
Gross Profit	$948.00M	$1.05B	$1.03B	$993.20M	$1.01B	$1.11B
Selling, General & Admin	$546.00M	$579.30M	$552.40M	$538.60M	$551.00M	$577.20M
Operating Expenses	$615.60M	$647.60M	$621.90M	$611.20M	$626.60M	$655.30M
Operating Income	$332.40M	$398.60M	$403.20M	$382.00M	$387.20M	$456.70M
EBITDA	$498.00M	$532.10M	$564.00M	$418.60M	$548.10M	$626.50M
Pretax Income	$275.20M	$304.70M	$337.00M	$190.60M	$319.70M	$386.40M
Income Tax	$62.20M	$66.40M	$75.50M	$25.70M	$41.70M	$87.30M
Net Income	$212.80M	$237.90M	$261.10M	$164.70M	$277.80M	$298.70M
Diluted EPS	2.52	2.84	3.12	1.98	3.35	3.64
Diluted Shares	84.30M	83.90M	83.70M	83.20M	82.90M	82.00M

LH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$369.40M	$647.30M	$598.10M	$532.30M	$981.10M	$141.80M
Receivables	$2.27B	$2.28B	$2.27B	$2.26B	$2.45B	$2.50B
Inventory	$488.30M	$508.10M	$521.50M	$534.70M	$497.70M	$562.20M
Current Assets	$3.79B	$4.09B	$4.08B	$4.02B	$4.56B	$3.81B
Total Assets	$17.60B	$18.06B	$18.26B	$18.39B	$19.09B	$18.53B
Current Liabilities	$2.06B	$2.72B	$2.63B	$2.82B	$2.64B	$2.12B
Long-Term Debt	$5.57B	$5.08B	$5.08B	$5.08B	$5.83B	$5.86B
Total Debt	$6.52B	$6.55B	$6.53B	$6.53B	$7.24B	$6.77B
Total Liabilities	$9.28B	$9.57B	$9.55B	$9.76B	$10.34B	$9.91B
Retained Earnings	$8.46B	$8.50B	$8.70B	$8.64B	$8.78B	$8.70B
Shareholders' Equity	$8.31B	$8.47B	$8.70B	$8.62B	$8.73B	$8.61B
Working Capital	$1.73B	$1.37B	$1.45B	$1.20B	$1.92B	$1.69B
Net Debt	$5.20B	$4.93B	$4.98B	$5.05B	$5.35B	$5.72B

LH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$18.50M	$620.60M	$387.20M	$614.20M	$191.50M	$445.50M
Capital Expenditure	-$126.00M	-$77.90M	-$106.70M	-$123.90M	-$121.00M	-$131.60M
Free Cash Flow	-$107.50M	$542.70M	$280.50M	$490.30M	$70.50M	$313.90M
Depreciation & Amortisation	$166.80M	$170.30M	$171.00M	$173.00M	$173.30M	$179.00M
Stock-Based Compensation	$32.80M	$34.10M	$29.20M	$29.70M	$31.70M	$34.90M
Investing Cash Flow	-$336.00M	-$94.10M	-$374.00M	-$389.90M	-$322.10M	-$366.20M
Financing Cash Flow	-$839.70M	-$267.40M	-$59.50M	-$290.40M	$580.50M	-$919.90M
Dividends Paid	-$61.60M	-$59.90M	-$59.90M	-$59.30M	-$61.20M	-$58.70M
Share Repurchases	$0.00	-$200.00M	-$25.00M	-$225.00M	-$98.00M	-$353.80M
Net Change in Cash	-$1.16B	$259.10M	-$46.30M	-$66.10M	$449.90M	-$840.60M

Market Snapshot

About

Labcorp Holdings Inc. is one of the world's leading global life sciences companies, providing comprehensive clinical laboratory and end-to-end drug development services. The company operates through two segments: Diagnostics Laboratories, offering routine and specialty testing services to healthcare providers and patients, and Biopharma Laboratory Services, supporting pharmaceutical companies in drug development from early research through post-market monitoring. Labcorp serves millions of patients and healthcare providers across more than 100 countries with a network of laboratories and patient service centers.